264 related articles for article (PubMed ID: 38652426)
1. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
5. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
8. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
10. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
Mjaess G; Aoun F; Rassy E; Diamand R; Albisinni S; Roumeguère T
Clin Genitourin Cancer; 2023 Feb; 21(1):171-174. PubMed ID: 35999150
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
13. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
14. Current status and future prospects of antibody-drug conjugates in urological malignancies.
Hayashi T; Hinata N
Int J Urol; 2022 Oct; 29(10):1100-1108. PubMed ID: 35581739
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
16. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
[TBL] [Abstract][Full Text] [Related]
19. Emerging agents for the treatment of metastatic urothelial cancer.
Kwon WA; Seo HK
Investig Clin Urol; 2021 May; 62(3):243-255. PubMed ID: 33943047
[TBL] [Abstract][Full Text] [Related]
20. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
Sternschuss M; Sarfaty M
Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]